Literature DB >> 6268958

The influence of different modes of immunization on the experimental genital herpes simplex virus infection of mice.

K E Schneweis, J Gruber, J Hilfenhaus, A Möslein, M Kayser, M H Wolff.   

Abstract

Previous investigations, which simulated the usual sequence of the human Herpes simplex virus (HSV) infections, had shown that the oral infection of mice with HSV-1 caused only weak protection from genital infection with HSV-2, although the course of infection was attenuated and lethality diminished. This heterologous, heterotopic model was compared with a homologous, heterotopic and a heterologous, homotopic model. The results did not differ very much, although the homologous immunization protected best from lethal outcome, the homotopic immunization best from local infection. Three different preparations of a killed vaccine from purified HSV-1 virion had little effect on the course of the local infection, although protection from lethal outcome was as good as with live virus. In contrast, a crude UV-inactivated vaccine protected nearly completely from local infection. Latent infection in the lumbosacral ganglia was significantly inhibited by immunization with live virus, but only slightly prevented by killed vaccine. The prevalence of latent infection correlated with the extent of vaginal infection. The results show that neither the viral type nor the inoculation site used for immunization with live virus are very critical. Moreover, they allow the conclusion that generalized type-dependent immune factors seem to be engaged in protection against lethal disease; these may be circulating humoral antibodies. On the other hand, locally induced immune factors (probably cellular) are apparently of prime importance for the protection from acute local and latent ganglionic infection.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6268958     DOI: 10.1007/bf02125526

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  26 in total

1.  Herpes simplex virus infection in sensory ganglia: immune control, latency, and reactivation.

Authors:  H Openshaw; A Puga; A L Notkins
Journal:  Fed Proc       Date:  1979-12

2.  Efficacy of a nucleic acid free herpetic subunit vaccine.

Authors:  R Cappel; F de Cuyper; F Rickaert
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

3.  [UV inactivation of Herpes simplex viruses, types 1 and 2].

Authors:  M H Wolff; K E Schneweis
Journal:  Zentralbl Bakteriol Orig A       Date:  1973-05

4.  6-Hydroxydopamine potentiates acute herpes simplex virus infection of the superior cervical ganglion in mice.

Authors:  R W Price
Journal:  Science       Date:  1979-08-03       Impact factor: 47.728

5.  Acute and latent infection of sensory ganglia with herpes simplex virus: immune control and virus reactivation.

Authors:  H Openshaw; L V Asher; C Wohlenberg; T Sekizawa; A L Notkins
Journal:  J Gen Virol       Date:  1979-07       Impact factor: 3.891

6.  Experimental infection of inbred mice with herpes simplex virus type 1. I. Investigation of humoral and cellular immunity and of interferon induction.

Authors:  R Zawatzky; J Hilfenhaus; F Marcucci; H Kirchner
Journal:  J Gen Virol       Date:  1981-03       Impact factor: 3.891

7.  Cell-mediated immunity against herpes simplex induction of cytotoxic T lymphocytes.

Authors:  M J Lawman; B T Rouse; R J Courtney; R D Walker
Journal:  Infect Immun       Date:  1980-01       Impact factor: 3.441

8.  Route of infection, systemic host resistance, and integrity of ganglionic axons influence acute and latent herpes simplex virus infection of the superior cervical ganglion.

Authors:  R W Price; J Schmitz
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

9.  Cell-mediated immunity to herpes simplex virus: induction of cytotoxic T lymphocyte responses by viral antigens incorporated into liposomes.

Authors:  M J Lawman; P T Naylor; L Huang; R J Courtney; B T Rouse
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

10.  Prepubertal vaccination of mice against experimental infection of the genital tract with type 2 herpes simplex virus.

Authors:  G R Skinner; D R Williams; A W Moles; A Sargent
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

View more
  7 in total

1.  Inhibition of the in vitro-reactivation of latent herpes simplex virus infection in spinal ganglia: comparison of various immune factors. Brief report.

Authors:  F von Rheinbaben; K E Schneweis
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

2.  Pathogenesis of genital herpes simplex virus infection in mice. III. Comparison of the virulence of wild and mutant strains.

Authors:  K E Schneweis; H Forstbauer; M Olbrich; M Tag
Journal:  Med Microbiol Immunol       Date:  1984       Impact factor: 3.402

3.  Pathogenesis of genital herpes simplex virus infection in mice. IV. Quantitative aspects of viral latency.

Authors:  A M Eis; K E Schneweis
Journal:  Med Microbiol Immunol       Date:  1986       Impact factor: 3.402

4.  Neurovirulence and latency in inbred mice of two HSV-1 intrastrain variants of divergent pathogenicity.

Authors:  G Kümel; C H Schröder; H C Kaerner
Journal:  Med Microbiol Immunol       Date:  1986       Impact factor: 3.402

5.  Comparison of effects of adjuvants on efficacy of virion envelope herpes simplex virus vaccine against labial infection of BALB/c mice.

Authors:  T A Thomson; J Hilfenhaus; H Moser; P S Morahan
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

Review 6.  Developments in herpes simplex virus vaccines: old problems and new challenges.

Authors:  J Rajcáni; V Durmanová
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.629

7.  Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light.

Authors:  A V Gracheva; E R Korchevaya; Yu I Ammour; D I Smirnova; O S Sokolova; G S Glukhov; A V Moiseenko; I V Zubarev; R V Samoilikov; I A Leneva; O A Svitich; V V Zverev; Evgeny B Faizuloev
Journal:  Arch Virol       Date:  2022-07-20       Impact factor: 2.685

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.